vidofludimus calcium (IMU-838) is an Immunic, Inc. program in relapsing multiple sclerosis. Its next catalyst is a Readout in Dec 2026. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: relapsing multiple sclerosis. Sponsor: Immunic, Inc. (IMUX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for vidofludimus calcium (IMU-838) is a Readout in Dec 2026.
No FDA decision for vidofludimus calcium (IMU-838) is in our archive yet.
In our records vidofludimus calcium (IMU-838) is under review or in development for relapsing multiple sclerosis.
Immunic, Inc. (IMUX).
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.